Merck & Co. (MRK)

NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-10-15

$145.95+0.52%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Merck & Co.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-2.8%

+10% or more+5%0%−5%−10% or less

9.55 → 9.28 EPS · FY ending Dec 31, 2027 · 13 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 14 to 13; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

4 key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Non-GAAP EPS at least $5.04 in 2026	A primary condition in Merck & Co.'s published investment case. The stated target is >= $5.04 per share.	Broken	EPS falls below $5.04 in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. Management narrowed and raised non-GAAP EPS guidance to $5.04-$5.16 in early 2026 but lowered it to $2.66-$2.76 by mid-2026, reflecting acquisition charges. Despite GAAP losses in 2026-Q1 and Q2, non-GAAP EPS guidance reflects adjusted expectations. The trajectory shows mixed delivery due to charges. Delivery assessment Oct 15, 2026
Manage impact of China drug trial investigations	A supporting condition in Merck & Co.'s published investment case. The stated target is No material regulatory penalties or operational disruptions.	Intact	Material penalties or operational disruptions from China investigations	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Advance oncology pipeline with new approvals and deals	New cancer drug approvals boost future sales.	Improving	No significant oncology approvals or pipeline advances in 12 months	Qualitative: 4 positive oncology pipeline events vs 1 negative Merck reported positive oncology trial results and vaccine expansion, though a court order blocked Keytruda SC in Europe. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue grows at least $65.8 billion in 2026	A primary condition in Merck & Co.'s published investment case. The stated target is >= $65.8 billion.	Under Pressure	Revenue falls below $65.8 billion in FY26	Revenue: $16.607B FY2026-Q2; GAAP. Published target: >= $65.8 billion. Target period is not explicitly aligned with this observation. Source published Aug 7, 202616,607,000,000 USD · source valueSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: f9e64b8c-411e-449c-a32e-4bd6a1493663. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 5 of last 5 quarters. Management raised and narrowed full-year revenue guidance from $65.5-$67.0B in early 2026 to $66.3-$67.3B by mid-2026. This reflects confidence in sales growth, consistent with reported quarterly revenues rising from $15.8B in 2025-Q2 to $16.6B in 2026-Q2. The trajectory is delivering. Delivery assessment Oct 15, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$9.28

$9.66 → $9.28 · observed estimates

FY2027 revenue$69.77B

$70.06B → $69.77B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$9.66	$70,059,972,180	16 / 15
2026-07-25	$9.66	$70,115,955,810	18 / 17
2026-07-26	$9.66	$70,115,955,810	18 / 17
2026-07-27	$9.66	$70,115,955,810	18 / 17
2026-07-28	$9.60	$70,179,708,490	11 / 13
2026-07-29	$9.64	$70,112,736,040	19 / 18
2026-07-30	$9.64	$70,112,736,040	19 / 18
2026-07-31	$9.64	$70,112,736,040	19 / 18
2026-08-01	$9.61	$70,152,262,303	11 / 14
2026-08-02	$9.68	$70,170,173,900	20 / 19
2026-08-03	$9.61	$70,171,008,083	12 / 14
2026-08-04	$9.61	$70,171,008,083	12 / 14
2026-08-05	$9.65	$70,109,745,200	21 / 20
2026-08-06	$9.61	$70,171,008,083	12 / 14
2026-08-07	$9.59	$70,222,088,814	12 / 15
2026-08-08	$9.60	$70,340,655,560	23 / 22
2026-08-09	$9.60	$70,340,655,560	23 / 22
2026-08-10	$9.59	$70,222,088,814	12 / 15
2026-08-12	$9.59	$70,222,088,814	12 / 15
2026-08-13	$9.59	$70,222,088,814	12 / 15
2026-08-14	$9.59	$70,222,088,814	12 / 15
2026-08-15	$9.59	$70,222,088,814	13 / 16
2026-08-16	$9.59	$70,222,088,814	13 / 16
2026-08-17	$9.59	$70,222,088,814	13 / 16
2026-08-18	$9.59	$70,222,088,814	13 / 16
2026-08-19	$9.59	$70,222,088,814	13 / 16
2026-08-20	$9.56	$70,239,710,622	14 / 17
2026-08-21	$9.54	$70,176,930,187	14 / 17
2026-08-22	$9.54	$70,176,932,583	14 / 17
2026-08-23	$9.54	$70,176,932,583	14 / 17
2026-08-24	$9.54	$70,176,932,583	14 / 17
2026-08-25	$9.54	$70,176,932,583	14 / 17
2026-08-26	$9.54	$70,188,604,583	14 / 17
2026-08-27	$9.54	$70,188,604,583	14 / 17
2026-08-28	$9.54	$70,188,604,583	14 / 17
2026-08-29	$9.54	$70,188,650,603	14 / 17
2026-08-30	$9.54	$70,188,650,603	14 / 17
2026-08-31	$9.54	$70,188,650,603	14 / 17
2026-09-01	$9.54	$70,188,650,603	14 / 17
2026-09-02	$9.54	$70,188,650,603	14 / 17
2026-09-03	$9.54	$70,188,650,603	14 / 17
2026-09-04	$9.54	$70,188,650,603	14 / 17
2026-09-05	$9.55	$70,190,844,583	14 / 17
2026-09-06	$9.55	$70,190,844,583	14 / 17
2026-09-07	$9.55	$70,190,844,583	14 / 17
2026-09-08	$9.55	$70,190,844,583	14 / 17
2026-09-09	$9.55	$70,194,164,583	14 / 17
2026-09-10	$9.55	$70,191,524,583	14 / 17
2026-09-11	$9.55	$70,192,840,770	14 / 17
2026-09-12	$9.55	$70,201,040,770	14 / 17
2026-09-13	$9.55	$70,201,040,770	14 / 17
2026-09-14	$9.55	$70,201,040,770	14 / 17
2026-09-15	$9.55	$70,201,040,770	14 / 17
2026-09-16	$9.55	$70,200,861,374	14 / 17
2026-09-17	$9.55	$70,200,861,374	14 / 17
2026-09-18	$9.55	$70,200,861,374	14 / 17
2026-09-19	$9.55	$70,200,861,374	14 / 17
2026-09-20	$9.55	$70,200,869,374	14 / 17
2026-09-21	$9.55	$70,200,869,374	14 / 17
2026-09-22	$9.55	$70,200,869,374	14 / 17
2026-09-23	$9.53	$70,179,245,378	14 / 17
2026-09-24	$9.53	$70,179,245,378	14 / 17
2026-09-25	$9.53	$70,179,245,378	14 / 17
2026-09-26	$9.53	$70,174,924,592	13 / 17
2026-09-27	$9.53	$70,174,924,592	13 / 17
2026-09-28	$9.53	$70,174,924,592	13 / 17
2026-09-29	$9.51	$70,161,164,592	13 / 17
2026-09-30	$9.51	$70,161,164,592	13 / 17
2026-10-01	$9.49	$70,127,475,000	13 / 17
2026-10-02	$9.49	$70,127,799,000	13 / 17
2026-10-03	$9.49	$70,127,799,000	13 / 17
2026-10-04	$9.49	$70,127,799,000	13 / 17
2026-10-05	$9.49	$70,127,799,000	13 / 17
2026-10-06	$9.47	$70,085,679,000	13 / 17
2026-10-07	$9.45	$70,049,679,000	13 / 17
2026-10-08	$9.43	$70,054,734,847	13 / 17
2026-10-09	$9.36	$69,938,636,616	13 / 18
2026-10-10	$9.36	$69,938,636,616	13 / 18
2026-10-11	$9.33	$69,903,578,377	13 / 18
2026-10-12	$9.33	$69,903,578,377	14 / 18
2026-10-13	$9.28	$69,770,371,467	14 / 18
2026-10-14	$9.28	$69,770,371,467	13 / 17
2026-10-15	$9.28	$69,770,371,467	13 / 17

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	19	10	0
2026-06-01	20	10	1
2026-07-01	19	9	1
2026-08-01	20	8	1
2026-09-01	20	8	0
2026-10-01	19	8	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 19 Buy / Strong Buy · 8 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades6 maintains

Recent actions · Sep 16–Oct 15 · 6 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

RBC CapitalOct 12 · prior Aug 20

$150.00 → $145.00-3.3%

Cantor FitzgeraldOct 8

$145.00New observation · no comparable prior

ScotiabankSep 29 · prior Jun 29

$155.00 → $180.00+16.1%

$0$99.00$198.00

1 raises · 1 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Non-GAAP EPS at least $5.04 in 2026Published status: Broken
Manage impact of China drug trial investigationsQualitative condition
Revenue grows at least $65.8 billion in 2026Published status: Under Pressure

Next proof point

Oct 29, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.2%Typical daily move · historical

Downside history

-11.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Merck & Co. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This investment represents a durable compounder with a focus on oncology and a strong pipeline. The current thesis is intact, bolstered by recent earnings beats and consistent management priorities.

What's priced into Merck & Co.

The valuation is considered expensive compared to peers, indicating that the market has high expectations for MRK's performance. There is an expectations gap, suggesting that the current price may not fully reflect the underlying fundamentals.

What the fundamentals likely do

Fundamentals are likely to remain strong, given the robust earnings quality and stable management. However, there are mixed signals regarding revenue and EPS guidance, which could introduce some near-term risks.

What Merck & Co. hinges on

The thesis hinges on MRK's ability to maintain its momentum in the oncology pipeline and manage guidance effectively. Additionally, the performance of sector peers like LLY, JNJ, and ABBV will be crucial for sustaining investor confidence.